Literature DB >> 7714799

[3H]WIN 35,428 binding in the caudate nucleus of the rabbit: evidence for a single site on the dopamine transporter.

V J Aloyo1, J S Ruffin, P S Pazdalski, A L Kirifides, J A Harvey.   

Abstract

The binding of the potent cocaine analog, WIN 35,428 ((-)-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane 1,5-napthalenedisulfonate), was investigated in adult Dutch Belted rabbits by using membrane fractions prepared from fresh caudate nucleus. The consistent finding of this study was that [3H]WIN 35,428 binds to a single class of sites. For example: 1) kinetic analysis revealed that the rate of association and dissociation of [3H]WIN 35,428 was linear; 2) analyses of saturation experiments or homotopic displacement with cold WIN 35,428 by three separate methods statistically favored a one-site model; and 3) heterotropic displacement with drugs that bind to the dopamine (DA) transporter consistently yielded only a single class of binding sites as reflected by a complete displacement of [3H]WIN 35,428 and Hill slopes of approximately 1 (range, 0.89-1.06). The rank order of potencies (Ki) obtained in the competition experiments was: mazindol > nomifensine > (-)-cocaine > bupropion > (-)-norcocaine >> desipramine > DA > (+)-cocaine >> norepinephrine > citalopram > 5-hydroxytryptamine. The affinities of these drugs at the [3H]WIN 35,428 binding site was significantly correlated (r = 0.96, P < .001) with their potencies for inhibiting the uptake of DA, but not the uptake of norepinephrine or 5-hydroxytryptamine. Because [3H]WIN 35,428 binding was fully displaced by cocaine and the displacement was stereoselective, with (-)-cocaine being 200-fold more potent than (+)-cocaine, we conclude that [3H]WIN 35,428 was binding to a single cocaine site. Taken together, these findings indicate that [3H]WIN 35,428 binds to a single cocaine site on the DA transporter of the rabbit with a Kd of 3.2 +/- 0.4 nM and a maximum binding of 0.39 +/- 0.04 pmol/mg of caudate tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714799

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

2.  Expression and distribution of dopamine transporter in cardiac tissues of the guinea pig.

Authors:  Alejandro Reynoso Palomar; Berenice Navarrete Larios; Victoria Chagoya De Sánchez; Lidia Martínez Pérez; Fidel De La Cruz López; Gonzalo Flores; Maria de Jesús Gómez-Villalobos
Journal:  Neurochem Res       Date:  2010-12-19       Impact factor: 3.996

3.  Effects of prenatal exposure to cocaine on the developing brain: anatomical, chemical, physiological and behavioral consequences.

Authors:  J A Harvey; A G Romano; M Gabriel; K J Simansky; W Du; V J Aloyo; E Friedman
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

4.  HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes.

Authors:  Jun Zhu; Charles F Mactutus; David R Wallace; Rosemarie M Booze
Journal:  J Pharmacol Exp Ther       Date:  2009-03-26       Impact factor: 4.030

5.  [18F]CFT synthesis and binding to monoamine transporters in rats.

Authors:  Sarita Forsback; Päivi Marjamäki; Olli Eskola; Jörgen Bergman; Johanna Rokka; Tove Grönroos; Merja Haaparanta; Olof Solin
Journal:  EJNMMI Res       Date:  2012-01-25       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.